BioAtla
BCAB
76 hedge funds and large institutions have $67.1M invested in BioAtla in 2022 Q2 according to their latest regulatory filings, with 18 funds opening new positions, 16 increasing their positions, 33 reducing their positions, and 35 closing their positions.
0.12% less ownership
Funds ownership: 1.43% → 1.31% (-0.12%)
22% less funds holding
Funds holding: 97 → 76 (-21)
35% less call options, than puts
Call options by funds: $105K | Put options by funds: $162K
47% less capital invested
Capital invested by funds: $128M → $67.1M (-$60.7M)
49% less first-time investments, than exits
New positions opened: 18 | Existing positions closed: 35
52% less repeat investments, than reductions
Existing positions increased: 16 | Existing positions reduced: 33
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tang Capital Management
San Diego,
California
|
+$7.23M |
| 2 |
RCM
RA Capital Management
Boston,
Massachusetts
|
+$3.28M |
| 3 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$2.38M |
| 4 |
Healthcare of Ontario Pension Plan (HOOPP) Trust Fund
Toronto,
Ontario, Canada
|
+$1.36M |
| 5 |
LCM
Laurion Capital Management
New York
|
+$931K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
-$8.29M |
| 2 |
BlackRock
New York
|
-$2.89M |
| 3 |
Wellington Management Group
Boston,
Massachusetts
|
-$2.83M |
| 4 |
Morgan Stanley
New York
|
-$1.64M |
| 5 |
DM
Deerfield Management
New York
|
-$1.45M |
BCAB Hedge Fund Activity: Q2 2022 in Review
76 of the 5,936 institutional investors tracked by Wall St. Rank reported a position in BioAtla (BCAB) for Q2 2022, worth a combined $67.1M — down 47% from $128M a quarter earlier.
Sellers outnumbered buyers: 35 funds closed out of BCAB and 18 opened new positions — a net loss of 17 holders — while 33 trimmed existing stakes and 16 added.
The largest buyer was Tang Capital Management, adding an estimated $7.23M. The largest seller was Fidelity Investments, cutting an estimated $8.29M.
- 76 institutional investors held BioAtla (BCAB) as of Q2 2022, down from 97 in Q1 2022.
- Funds reported $67.1M of BioAtla stock for Q2 2022, down 47% quarter-over-quarter.
- 18 funds opened new BioAtla positions in Q2 2022 and 35 closed out, a net change of -17 holders.
- The largest BioAtla buyer in Q2 2022 was Tang Capital Management, an estimated $7.23M added.
- The largest BioAtla seller in Q2 2022 was Fidelity Investments, an estimated $8.29M sold.
Based on aggregated 13F filings for Q2 2022.